Threshold Pharmaceuticals Fund Company Profile

Description

Threshold Pharmaceuticals, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule is evofosfamide, which is in two Phase III clinical trials for the treatment of soft tissue sarcoma indication and advanced pancreatic cancer; Phase II clinical trials for treating non-squamous non-small cell lung cancer; Phase II clinical trials for advanced melanoma; and Phase I/II clinical trials for multiple myeloma. The company is also involved in the study of evofosfamide in investigator sponsored trials, including Phase I/II clinical trials for glioblastoma; Phase I clinical trials for advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors; Phase II clinical trials for glioblastoma and pancreatic neuroendocrine tumors; Phase I clinical trials for advanced solid tumors; and Phase I/II clinical trials for advanced kidney cancer or liver cancer. In addition, it engages in developing Tarloxotinib, an investigational hypoxia-activated EGFR tyrosine kinase inhibitor, which is in two Phase II clinical trials for patients with advanced non-squamous non-small cell lung cancer, as well as patients with squamous cell carcinomas of the head, neck, or skin; and [18F]-HX4, an investigational PET imaging agent for hypoxia. The company has a license and co-development agreement with Merck KGaA to co-develop and commercialize evofosfamide; license agreement with Auckland UniServices Ltd. for the development program based on Tarloxotinib; and license agreement with Eleison Pharmaceuticals, Inc. for the manufacture, development, and commercialization of glufosfamide for the treatment of cancer in humans and animals, as well as other uses. Threshold Pharmaceuticals, Inc. was founded in 2001 and is headquartered in South San Francisco, California.